Pharmacists are uniquely poised for harm reduction work due to their accessibility, medication expertise, and direct patient interaction. They can provide non-prescription syringes, dispense naloxone and medication for opioid use disorder, offer human immunodeficiency virus and hepatitis C virus testing, administer vaccines for hepatitis B virus and human papillomavirus, and prescribe pre- and post-exposure prophylaxis. Despite these advancements, ongoing barriers such as restrictive pharmacy policies and stigma persist, and gaps in education contribute to the problem. Currently, harm reduction education is underrepresented in the Doctor of Pharmacy curriculum. This commentary highlights existing gaps in pharmacist training, emerging pilot programs, and makes practical recommendations for integration of harm reduction education, including minimal competencies, curricular mapping, and implementation strategies to facilitate uptake.
Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS publication no. PEP23-07-01-006, NSDUH series H-58). Updated November 13, 2023. Accessed April 7, 2024. https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report
SpencerMRGarnettMFMiniñoAM. Drug overdose deaths in the United States, 2002-2022. NCHS Data Brief, no 491. Hyattsville, MD: National Center for Health Statistics; 2024.
Chan CarusoneSGutaARobinsonS, et al. “Maybe if I stop the drugs, then maybe they’d care?”—hospital care experiences of people who use drugs. Harm Reduct J. 2019;16(1):16.
BurgessABauerEGallagherS, et al. Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: a qualitative analysis. J Subst Abuse Treat. 2021;130:108488.
RussellDMMeyersonBEMahoneyAN, et al. Come back when you’re infected: pharmacy access to sterile syringes in an Arizona Secret Shopper Study, 2023. Harm Reduct J. 2024;21(1):49.
10.
TrullGMajorEHarlessCZuleWOstrachBCarpenterD.Rural community pharmacist willingness to dispense Suboxone®—a secret shopper investigation in South-Central Appalachia. Explor Res Clin Soc Pharm. 2021;4:100082.
11.
MarleyGBlytheEWestrickSCarpenterDM.Availability of and attitudes toward harm reduction services: a rural pharmacy perspective. J Am Pharm Assoc. 2025;65(2):102291.
12.
GilbertLElliottJBeasleyLOranuERothKNguyenJ.Naloxone availability in independent community pharmacies in Georgia, 2019. Subst Abuse Treat Prev Policy. 2021;16(1):63.
13.
ContrerasJBausCBrandtCWitryMPetersJEvoyKE.Pharmacist counseling when dispensing naloxone by standing order: a secret shopper study of 4 chain pharmacies. J Am Pharm Assoc. 2021;61(2):e94-e99.
MarleyGTOstrachBCarpenterD.North Carolina pharmacists’ willingness to sell fentanyl test strips: a survey study. Harm Reduct J. 2023;20(1):10.
16.
RawalSKhailJWStoneRHYoungHN.The availability of fentanyl test strips in Georgia community pharmacies. J Am Pharm Assoc. 2024;64(2):524-529.e1.
17.
WeinerSGQatoDMFaustJSClearB.Pharmacy availability of buprenorphine for opioid use disorder treatment in the US. JAMA Netw Open. 2023;6(5):e2316089.
18.
KazerouniNJIrwinANLevanderXA, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.
19.
SoEBrandsMSuomalaE, et al. Pharmacists’ opinions on the implementation of HIV and HepC point-of-care-testing in a U.S. pharmacy chain. Innov Pharm. 2019;10(1):e1425.
20.
Dowling-McClayKMathisSMHagemeierN.Community pharmacist engagement in HIV and HCV prevention: current practices and potential for service uptake. Explor Res Clin Soc Pharm. 2021;4:100088.
HiltsKECorelliRLVernonVPHudmonKS.Update and recommendations: pharmacists’ prescriptive authority for tobacco cessation medications in the United States. J Am Pharm Assoc. 2022;62(5):1531-1537.
25.
AdamsAJKlepserME.Pharmacy-based assessment and management of herpes labialis (cold sores) with antiviral therapy. Innov Pharm. 2020;11(3):e1532.
LevengoodTWYoonGHDavoustMJ, et al. Supervised injection facilities as harm reduction: a systematic review. Am J Prev Med. 2021;61(5):738-749.
30.
KutscherEBarber GrossiMLaPollaFLeeJD.Fentanyl test strips for harm reduction: a scoping review. J Addict Med. 2024;18(4):373-380.
31.
TaylorJLJohnsonSCruzRGrayJRSchiffDBagleySM.Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810-3819.
32.
RosenJGZhangLPelaezDParkJNGlickJL.A capacity-strengthening intervention to support HIV pre-exposure prophylaxis (PrEP) awareness-building and promotion by frontline harm reduction workers in Baltimore, Maryland: a mixed methods evaluation. AIDS Behav. 2023;27(7):2440-2453.
33.
MontgomeryMPZhongYRobertsE, et al. Vaccination barriers and opportunities at syringe services programs in the United States, June-August 2021—a cross-sectional survey. Drug Alcohol Depend. 2022;237:109540.
34.
GrauLEArevaloSCatchpoolCHeimerR.Expanding harm reduction services through a wound and abscess clinic. Am J Public Health. 2002;92(12):1915-1917.
35.
SanchezDPTookesHPastarILev-TovH.Wounds and skin and soft tissue infections in people who inject drugs and the utility of syringe service programs in their management. Adv Wound Care. 2021;10(10):571-582.
36.
HaganHMcGoughJPThiedeHHopkinsSDuchinJAlexanderER.Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247-252.
37.
ThomasKMuzykAJ.Surveys of substance use disorders education in US pharmacy programs. Ment Health Clin. 2018;8(1):14-17.
38.
TranTBallJBratbergJP, et al. Report of the 2020 special committee on substance use and pharmacy education. Am J Pharm Educ. 2020;84(11):8421.
39.
BrownPCMButtonDABethuneD, et al. Assessing student readiness to work with people who use drugs: development of a multi-disciplinary addiction educational survey. J Gen Intern Med. 2022;37(15):3900-3906.
40.
GortonHCStrawbridgeJMacfarlaneH.Mental health: “it is a subject where most pharmacists [or pharmacy] students have no more knowledge than the general public”. J Pharm Policy Pract. 2023;16(1):13.
41.
MahonLRHawthorneANLeeJBlueHPalombiL.Assessing pharmacy student experience with, knowledge of and attitudes towards harm reduction: illuminating barriers to pharmacist-led harm reduction. Harm Reduct J. 2018;15(1):57.
42.
HarrisSCBostwickJRWerremeyerABGoldstoneLWCatesMECaleyCF.Addressing the conflict between promoting wellness, perpetuating mental illness stigma and making psychiatric pharmacy education less intense. Am J Pharm Educ. 2021;85(7):8354.
43.
NicholsMARileyEGChaoAS, et al. Opioid use disorder curricular content in US-based Doctor of Pharmacy programs. Am J Pharm Educ. 2023;87(6):100061.
44.
DavisBMcDanielCCWangCHGarzaKB.Mental health and psychotropic stigma among student pharmacists. Front Public Health. 2022;10:818034.
45.
LoeraLJHillLGZagorskiCMJermainMLTiradoCF.Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 2023;87(1):ajpe8926.
46.
MaguireMAPavlakosRNMehtaBHSchmuhlKKBeattySJ.A naloxone and harm reduction educational program across four years of a Doctor of Pharmacy program. Curr Pharm Teach Learn. 2018;10(1):72-77.
DionKChoiJGriggsS.Building therapeutic commitment in university nursing students. Nurse Educ. 2022;47(2):86-90.
53.
DamewoodADavisSKBeebeLH.Integrated education reduces negative attitudes toward persons with substance use disorders: a pilot study. Issues Ment Health Nurs. 2022;43(6):528-531.
54.
JankuCDe SaLDaniyanA.An introduction to harm reduction for medical students: addressing stigma through an interactive preclerkship lecture. Cureus. 2023;15(8):e44076.
55.
AvraTCowanAFriedmanJ, et al. Decreasing stigma toward people who inject drugs: harm reduction training for first-year medical students. Acad Med. 2024;99(6):613-617.
Grayken Center for Addiction Training and Technical Assistance, Boston Medical Center. 2025. Accessed April 23, 2025. https://www.addictiontraining.org/
58.
KolanczykDMMerioJBradleyBFlanneryAH.2023 Update to the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. J Am Coll Clin Pharm. 2024;7(3):255-269.
